Increasingly common with immunotherapy against cancer A study has been underway at the University Hospital since the spring of 2018, in which a virus is used as a carrier of immune-stimulating genes. The target group is patients with non-operable cancer originating in the pancreas, colon and rectum, bile ducts or ovaries. For cancer patients, immunotherapy is increasingly seen as the fourth cornerstone of the treatment arsenal alongside surgery, radiation therapy and chemotherapy. - The hope is that the treatment will prove effective, without causing severe side effects, and thus can be registered as a drug for clinical use, says Gustav Ullenhag, chief physician and associate professor at the cancer clinic, Akademiska sjukhuset and researcher in translational immunotherapy, Uppsala University. Cancer cells burst The researchers use a so-called oncolytic virus, which was developed by Professor Angelica Loskog's research group at Uppsala University together with a pharmaceuti...